Business
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
Webinar to be held Tuesday, December 2nd, at 8:00 am ETREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the Company will host a webinar to present fi
About this update from Jasper Therapeutics, Inc.
[{"type":"image","alt":"Jasper Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Jasper Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/3e2f430d18dcba99f4639e0554ffa243"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LLcnUvvYBgfV.hnPSLdbkQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3e2f430d18dcba99f4639e0554ffa243","width":300,"height":107}},"lazy":false},{"type":"text","content":"Webinar to be held Tuesday, December 2nd, at 8:00 am ET","length":55,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the Company will host a webinar to present findings from its investigation into the anomalous results from the BEACON study in CSU reported in July, as well as preliminary data from the ETESIAN study in asthma. The webinar will include remarks from Jasper management as well as Dr. Martin Metz, M.D., Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, and lead EU investigator in the BEACON study. A live question and answer session will follow the formal presentation.","length":894,"tagName":"p"},{"type":"text","content":"Registration details for the webinar are as follows:","length":52,"tagName":"p"},{"type":"text","content":"Jasper Therapeutics Investor Webinar","length":36,"tagName":"p"},{"type":"text","content":"Tuesday, December 2, 2025 - 8:00 am ET","length":38,"tagName":"p"},{"type":"text","content":"Registration Link: Click Here","length":29,"tagName":"p"},{"type":"text","content":"The presentation slides and a link to the live and archived webcast will also be available on the Events & News – Events page of Jasper's Investor Relations website.","length":173,"tagName":"p"},{"type":"text","content":"About Jasper ","length":12,"tagName":"p"},{"type":"text","content":"Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeu...